

# Carl Turesson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4217826/publications.pdf>

Version: 2024-02-01

84  
papers

4,762  
citations

109321  
35  
h-index

98798  
67  
g-index

88  
all docs

88  
docs citations

88  
times ranked

4758  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. <i>Rheumatology</i> , 2022, 61, 3952-3962.	1.9	17
2	Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 789-797.	0.9	9
3	Multimomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1085-1095.	0.9	26
4	Male Sex Predicts a Favorable Outcome in Early ACPA-negative Rheumatoid Arthritis: Data From An Observational Study.. <i>Journal of Rheumatology</i> , 2022, ,jrheum.211199.	2.0	1
5	An update on polymyalgia rheumatica. <i>Journal of Internal Medicine</i> , 2022, 292, 717-732.	6.0	27
6	Infections Are Associated With Increased Risk of Giant Cell Arteritis: A Population-based Case-control Study from Southern Sweden. <i>Journal of Rheumatology</i> , 2021, 48, 251-257.	2.0	16
7	Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 921-930.	5.6	17
8	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. <i>Rheumatology</i> , 2021, 60, 820-828.	1.9	41
9	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1086-1093.	0.9	79
10	Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply. <i>Rheumatology</i> , 2021, 60, e262-e263.	1.9	0
11	Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate. <i>Rheumatology</i> , 2021, 61, 146-153.	1.9	16
12	Trajectory of Healthcare Resource Utilization in Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021, 48, 1307-1313.	2.0	1
13	Evaluation of revised classification criteria for giant cell arteritis and its clinical phenotypes. <i>Rheumatology</i> , 2021, , .	1.9	6
14	Autoantibodies in Rheumatoid Arthritis — Laboratory and Clinical Perspectives. <i>Frontiers in Immunology</i> , 2021, 12, 685312.	4.8	43
15	Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis—an inception cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 169.	3.5	18
16	Comment on: Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate: reply. <i>Rheumatology</i> , 2021, 60, e423-e424.	1.9	1
17	Lifestyle Factors and Disease Activity over Time in Early Axial Spondyloarthritis - The SPondyloArthritis Caught Early (SPACE) Cohort. <i>Journal of Rheumatology</i> , 2021, ,jrheum.210046.	2.0	3
18	Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 27.	3.5	10

#	ARTICLE	IF	CITATIONS
19	Proteomic Data Analysis for Differential Profiling of the Autoimmune Diseases SLE, RA, SS, and ANCA-Associated Vasculitis. <i>Journal of Proteome Research</i> , 2021, 20, 1252-1260.	3.7	5
20	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. <i>RMD Open</i> , 2021, 7, e001987.	3.8	13
21	Malignancies in Giant Cell Arteritis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2020, 47, 400-406.	2.0	10
22	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
23	Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1040-1048.	3.4	81
24	Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001142.	3.8	8
25	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.9	11
26	Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3229-3236.	1.9	30
27	Validity of polymyalgia rheumatica diagnoses and classification criteria in primary health care. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz033.	0.7	6
28	164. INCIDENCE AND SEASONAL VARIATION OF BIOPSY-PROVEN GIANT CELL ARTERITIS – REVISITED A 20 YEARS POPULATION-BASED STUDY FROM SWEDEN. <i>Rheumatology</i> , 2019, 58, .	1.9	0
29	165. INFECTIONS ARE ASSOCIATED WITH INCREASED RISK OF GIANT CELL ARTERITIS - A POPULATION-BASED CASE-CONTROL STUDY FROM SOUTHERN SWEDEN. <i>Rheumatology</i> , 2019, 58, .	1.9	0
30	The relation between upper extremity joint involvement and grip force in early rheumatoid arthritis: a retrospective study. <i>Rheumatology International</i> , 2019, 39, 2031-2041.	3.0	4
31	Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2019, 39, 1575-1584.	3.0	7
32	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. <i>RMD Open</i> , 2019, 5, e000994.	3.8	22
33	The Relation Between Disease Activity, Patient-Reported Outcomes, and Grip Force Over Time in Early Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 507-515.	2.1	3
34	Course of Grip Force Impairment in Patients With Early Rheumatoid Arthritis Over the First Five Years After Diagnosis. <i>Arthritis Care and Research</i> , 2018, 70, 491-498.	3.4	21
35	Smoking, disease characteristics and serum cytokine levels in patients with primary Sjögren's syndrome. <i>Rheumatology International</i> , 2018, 38, 1503-1510.	3.0	15
36	Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Current Therapeutic Research</i> , 2018, 89, 1-6.	1.2	19

#	ARTICLE	IF	CITATIONS
37	Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 82.	3.5	44
38	Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2018, 169, 291-299.	3.9	53
39	Cigarette smoking and the risk of primary Sjögren's syndrome: a nested case control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 50.	3.5	26
40	Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2017, 44, 981-987.	2.0	23
41	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the European-European registry collaboration for abatacept (PANABA). <i>Clinical Rheumatology</i> , 2017, 36, 773-779.	2.2	33
42	Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2017, 44, 84-90.	2.0	43
43	The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 363.	1.9	37
44	Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2016, 43, 1559-1565.	2.0	59
45	A high body mass index is associated with reduced risk of rheumatoid arthritis in men, but not in women. <i>Rheumatology</i> , 2016, 55, 307-314.	1.9	33
46	Comorbidity in rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2016, 146, w14290.	1.6	29
47	High serum cholesterol predicts rheumatoid arthritis in women, but not in men: a prospective study. <i>Arthritis Research and Therapy</i> , 2015, 17, 284.	3.5	23
48	Parity influences the severity of ACPA-negative early rheumatoid arthritis: a cohort study based on the Swedish EIRA material. <i>Arthritis Research and Therapy</i> , 2015, 17, 358.	3.5	3
49	Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 993-997.	0.9	100
50	The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. <i>Arthritis Research and Therapy</i> , 2015, 17, 118.	3.5	77
51	Nitrosative modifications of the Ca <sup>2+</sup> release complex and actin underlie arthritis-induced muscle weakness. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1907-1914.	0.9	40
52	Body mass index and the risk of giant cell arteritis—results from a prospective study. <i>Rheumatology</i> , 2015, 54, 433-440.	1.9	33
53	The impact of obesity on the development and progression of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1911-1913.	0.9	42
54	Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA—results from a community based study. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 44.	1.9	20

#	ARTICLE	IF	CITATIONS
55	Association between testosterone levels and risk of future rheumatoid arthritis in men: a population-based caseâ€“control study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 573-579.	0.9	57
56	Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 883-90.	0.8	5
57	The prevalence of moderate to severe radiographic sacroiliitis and the correlation with health status in elderly Swedish men â€“ The MrOS study. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 352.	1.9	9
58	Extra-articular rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 360-366.	4.3	90
59	Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2047-2048.	0.9	19
60	Early menopause is an independent predictor of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 378-381.	0.9	101
61	Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 520-522.	0.9	30
62	Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis - results from a well defined population in south Sweden. <i>Arthritis Research and Therapy</i> , 2011, 13, R67.	3.5	72
63	Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 2005-2013.	1.9	187
64	Incidence of Extraarticular Rheumatoid Arthritis in Olmsted County, Minnesota, in 1995â€“2007 Versus 1985â€“1994: A Population-based Study. <i>Journal of Rheumatology</i> , 2011, 38, 983-989.	2.0	143
65	Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden. <i>Rheumatology</i> , 2009, 48, 1600-1605.	1.9	43
66	High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 416-420.	1.9	59
67	Vasculitis in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 35-40.	4.3	72
68	Cardiovascular co-morbidity in rheumatic diseases. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 605-614.	2.3	91
69	Clustering of extraarticular manifestations in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 179-80.	2.0	27
70	Cardiovascular risk factors, fitness and physical activity in rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2007, 19, 190-196.	4.3	65
71	CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 43-57.	6.7	70
72	Genetics of Rheumatoid Arthritis. <i>Mayo Clinic Proceedings</i> , 2006, 81, 94-101.	3.0	75

#	ARTICLE	IF	CITATIONS
73	Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis and Rheumatism, 2006, 54, 635-641.	6.7	82
74	Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 2776-2783.	6.7	71
75	Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis and Rheumatism, 2005, 52, 73-79.	6.7	83
76	The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Research and Therapy, 2005, 7, R1386.	3.5	84
77	Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 1213-8.	2.0	380
78	No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: Results from a community-based study. Arthritis and Rheumatism, 2004, 50, 3729-3731.	6.7	42
79	Genetics of rheumatoid arthritis: Is there a pattern predicting extraarticular manifestations?. Arthritis and Rheumatism, 2004, 51, 853-863.	6.7	32
80	Management of extra-articular disease manifestations in rheumatoid arthritis. Current Opinion in Rheumatology, 2004, 16, 206-211.	4.3	59
81	Endothelial Expression of MHC Class II Molecules in Autoimmune Disease. Current Pharmaceutical Design, 2004, 10, 129-143.	1.9	57
82	Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years. Arthritis and Rheumatism, 2003, 48, 54-58.	6.7	423
83	Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 62-7.	2.0	204
84	Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis and Rheumatism, 2001, 44, 1170-1176.	6.7	59